氢化可的松对重症COVID-19患者死亡率及器官支持的影响:REMAP-CAP皮质类固醇域随机临床试验
REMAP-CAP平台试验在8国121中心纳入614例重症COVID-19成人患者,其中403例随机分配至皮质类固醇域。固定剂量氢化可的松组与无氢化可的松组相比,21天内无器官支持天数的优势概率为93%,但未达预设优越性阈值(>99%),试验提前终止,无法定论。
要点
- 固定剂量氢化可的松组优势概率93%,未达预设>99%阈值。
- 休克依赖剂量组优势概率80%,同样未达优越性标准。
- 试验提前终止,无法就氢化可的松疗效得出确定性结论。
核心结论
- 固定剂量氢化可的松和休克依赖剂量氢化可的松相较于无氢化可的松,在21天内无器官支持天数改善的优越概率分别为93%和80%。
- 但试验提前终止,且无治疗策略达到预设的统计优越性标准,无法得出确定性结论。
研究设计与样本
- 采用持续进行的适应性平台试验,在多个治疗域(如抗病毒药物、皮质类固醇、免疫球蛋白)中测试多种干预措施。
- 2020年3月9日至6月17日,在8个国家121个中心纳入614例疑似或确诊COVID-19成人患者,因呼吸或心血管器官支持入住ICU后随机分组。
- 其中403例被随机分配至皮质类固醇域的开放标签干预;另一试验结果公布后该域提前终止,随访于2020年8月12日结束。
主要发现
- 排除19例撤回知情同意者后,384例患者随机分配至固定剂量组(n=137)、休克依赖组(n=146)和无氢化可的松组(n=101);379例(99%)完成研究并纳入分析。
- 三组平均年龄为59.5至60.4岁,男性占70.6%至71.5%,平均BMI为29.7至30.9,接受机械通气者占50.0%至63.5%。
- 固定剂量组、休克依赖组和无氢化可的松组的中位无器官支持天数分别为0天(IQR,-1至15)、0天(IQR,-1至13)和0天(IQR,-1至11)。
- 三组死亡率分别为30%、26%和33%,幸存者中位无器官支持天数分别为11.5天、9.5天和6天。
- 固定剂量氢化可的松对比无氢化可的松的中位调整比值比为1.43(95%可信区间,0.91-2.27),优越概率93%;休克依赖剂量对比无氢化可的松的中位调整比值比为1.22(95%可信区间,0.76-1.94),优越概率80%。
关键数值与推荐
- 优越性定义为比值比大于1的后验概率超过99%(试验优越性结论阈值>99%)。
- 主要终点为21天内无器官支持天数(存活且无需ICU呼吸或心血管支持的天数),死亡患者记为-1天。
- 固定剂量氢化可的松为7天静脉疗程(50 mg或100 mg每6小时一次);休克依赖剂量为临床出现休克时50 mg每6小时一次。
临床怎么用
- 该试验未达到预设统计优越性标准且提前终止,不能据此确定氢化可的松在重症COVID-19中的常规使用。
- 临床决策需结合其他临床试验结果及患者个体情况综合判断。
局限性
- 试验因另一试验结果公布而提前终止,可能影响统计效能。
- 无治疗策略达到预设的统计优越性标准,无法得出确定性结论。
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. OBJECTIVE: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. INTERVENTIONS: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). MAIN OUTCOMES AND MEASURES: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). RESULTS: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.
引用
- Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020. PMID: 32876697. doi:10.1001/jama.2020.17022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。